1. Home
  2. ETON vs PRTA Comparison

ETON vs PRTA Comparison

Compare ETON & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eton Pharmaceuticals Inc.

ETON

Eton Pharmaceuticals Inc.

HOLD

Current Price

$16.57

Market Cap

498.8M

Sector

Health Care

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$11.02

Market Cap

595.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETON
PRTA
Founded
2017
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
498.8M
595.9M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ETON
PRTA
Price
$16.57
$11.02
Analyst Decision
Strong Buy
Buy
Analyst Count
3
9
Target Price
$29.67
$18.86
AVG Volume (30 Days)
326.6K
621.0K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$70,316,000.00
$11,786,000.00
Revenue This Year
$113.27
N/A
Revenue Next Year
$36.70
$819.08
P/E Ratio
N/A
N/A
Revenue Growth
102.77
N/A
52 Week Low
$11.09
$4.32
52 Week High
$23.00
$17.66

Technical Indicators

Market Signals
Indicator
ETON
PRTA
Relative Strength Index (RSI) 43.62 59.50
Support Level $15.28 $10.14
Resistance Level $17.00 $11.57
Average True Range (ATR) 0.82 0.57
MACD 0.06 0.06
Stochastic Oscillator 38.55 71.70

Price Performance

Historical Comparison
ETON
PRTA

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Share on Social Networks: